Blood and Urine Biomarkers for Assessing Dialysis Adequacy in Chronic and End-Stage Kidney Disease: A Systematic Review
Clicks: 1
ID: 314159
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #248 of 254 articles by views in Yemen Journal of Medicine
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: Traditional dialysis adequacy assessment relies on urea-based kinetics, such as Kt/V, which overlooks aspects of uremic toxicity, including middle molecule buildup, inflammation, and tubular stress. Blood and urine biomarkers provide a more comprehensive and personalized approach. This systematic review evaluates their prognostic and diagnostic value for dialysis adequacy and clinical outcomes in adults with chronic kidney disease (CKD) stages 4 to 5 and end-stage kidney disease (ESKD).
Methods: Following PRISMA 2020 guidelines, we searched PubMed/MEDLINE, EMBASE, Cochrane Library, and Web of Science (January 2000–December 2025) for relevant studies. Two reviewers independently handled selection, extraction, and quality assessment via the Newcastle-Ottawa Scale and Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Results: Of 2847 records, 48 studies (n = 41,326 patients) were included. Inflammatory biomarkers (e.g., sTNFR1, sTNFR2, CRP) were strongly associated with all-cause and cardiovascular mortality (pooled HR for sTNFR1, 1.86 [95% CI, 1.58–2.19]). Middle molecules (β2-microglobulin) and protein-bound toxins (indoxyl sulfate) are linked to mortality and cardiovascular events. Urinary tubular injury markers (NGAL, KIM-1) predicted residual kidney function (RKF) decline in hemodialysis and peritoneal dialysis, for example, 25% faster RKF loss per 50% urinary KIM-1 increase over 18 months in PD cohorts, with independent prognostic value for ESKD progression. Biomarkers often added value beyond Kt/V, though assay heterogeneity, timing, and normalization hindered comparisons.
Conclusions: Blood and urine biomarkers deliver pathophysiological insights surpassing urea kinetics, promising personalized dialysis. Translation requires assay standardization, decision thresholds, and interventional trials confirming that biomarker-guided strategies improve outcomes.
| Reference Key |
2026blood
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Elmukhtar Habas, Hafedh Ghazouani, Ala Habas, Khaled Alarabi, Eshrak Habas, Amnna Rayani |
| Journal | Yemen Journal of Medicine |
| Year | 2026 |
| DOI |
10.63475/yjm.v5i1.0283
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.